| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377424 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
Structure based ligand design was used in order to design a partial agonist for the PPARδ receptor. The maximum activation in the transactivation assay was reduced from 87% to 39%. The crystal structure of the ligand binding domain of the PPARδ receptor in complex with compound 2 was determined in order to understand the structural changes which gave rise to the decrease in maximum activation.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Ingrid Pettersson, Søren Ebdrup, Miroslav Havranek, Pavel Pihera, Marek Kořínek, John P. Mogensen, Claus B. Jeppesen, Eva Johansson, Per Sauerberg,